CHEST Members

Membership & Community

If you want to make your mark in the community of chest medicine, you’ve come to the right place. Share an opinion, submit an idea, comment on a thread—this is the place where you can expand your circle of peers to get more of what you want out of CHEST.

Welcome back

Başak Çoruh, MD, FCCP, and Meredith Pugh, MD, MSCI

Meet our expert board review educators

CHEST Critical Care Board Review 2022 is fast approaching. Meet two of the expert faculty who will be guiding you through preparation for your exams: Chair, Başak Çoruh, MD, FCCP, and Vice-Chair, Meredith Pugh, MD, MSCI. Learn more about their backgrounds and teaching philosophy.


CHEST Advocates

Lead the voice of CHEST advocacy

CHEST is seeking an editor to lead CHEST Advocates, a new publication dedicated to illuminating regulatory, legislative, diversity, and other issues impacting the way clinicians practice and identifying opportunities to improve care for patients. Take this opportunity to guide the development of content that helps clinicians champion for their patients and their practice and drives CHEST’s mission to crush lung disease forward.


Call for Editors in Chief

Lead the journal CHEST into a new era

The CHEST® journal portfolio will expand in 2023 with the launch of two new open access journals: CHEST Critical Care and CHEST Pulmonary. Apply to lead the launch and development of one of these journals as Editor in Chief. Applications are being accepted through Thursday, May 26.



Conversation starters: Topics you want to discuss

Richa Nahar, MD, and Allen J. Blaivas, DO, FCCP

Betting on asthma: The over and under of diagnosis

It is estimated that as many as 70% of people with asthma worldwide remain undiagnosed. CHEST members Richa Nahar, MD, and Allen J. Blaivas, DO, FCCP, review the latest research on asthma diagnosis, identifying the global consequences of both overdiagnosis and underdiagnosis and the need for new standardized algorithms with improved biomarkers to ensure more accurate evaluation.


Adrian Shifren, MD, and Gabriel Schroeder, MD

Future therapies for IPF

Only two drugs are currently FDA-approved for treatment of idiopathic pulmonary fibrosis (IPF). In this CHEST Physician® article, members Adrian Shifren, MD, and Gabriel Schroeder, MD, explore the current and emerging treatment options for IPF.


Submit an idea

Do you have a great idea?

If you’re as passionate about pulmonary, critical care, and sleep medicine as we are, you’re probably bursting with ideas on how we can advance those fields. Maybe you want to create a new practice tool or a different educational approach, or perhaps you want to create a patient resource. Let us know what you’re thinking, and we’ll see if we can get it off the ground together.


Join the conversation on social media and connect with members of the CHEST community.

Facebook icon Twitter icon Linked in icon YouTube icon Instagram icon

Advance your career. Become an FCCP.

When you become an FCCP (Fellow of the American College of Chest Physicians), you play an active role in advancing the field of chest medicine while enjoying the prestige of being associated with a distinctive group of chest medicine professionals.

“For me, obtaining FCCP was quite an honor and very important for career development—promotion, being asked to give talks, write papers, and more.”

– Carolyn M. D'Ambrosio, MD, MS, FCCP